文摘
摘要目的:调查的速度突破SARS-CoV-2感染和临床结果在一群女士的患者接受ocrelizumab之前第一,第二,第三BNT162b2 mRNA接种疫苗。
背景:研究包括参与者从三个女士诊所在丹麦和加州大学,旧金山在美国当οBA.1 SARS-CoV-2和BA.2是主导的亚型。减少体液反应与ocrelizumab治疗多发性硬化症(MS)。
设计/方法:这项研究是前瞻性非随机对照观察多中心试验。参与者被诊断为多发性硬化症和收到ocrelizumab治疗> 12个月前三个BNT162b2 mRNA接种疫苗。在随访期为2021年1月至2022年5月。临床结果评估使用发展规模。参与者的体液和细胞免疫原性与PCR证实突破感染。
结果:54岁的参与者,32例(59.3%)开发了一种积极SARS-CoV-2 PCR测试在研究期间。轻度感染被观察到在所有被感染的参与者。第三个疫苗接种后,未受感染的参与者有更高的意思是受感染的参与者相比,抗体水平(54.3 vs 26.5鲍起静/ mL, p = 0.030)。spike-specific CD4之间反应的差异+和CD8+非标准t淋巴球在两组。额外的结果关于ocrelizumab水平,anti-ocrelizumab抗体和SARS-CoV-2核衣壳蛋白,结合第四接种疫苗的免疫效果将会在会议上提出。
结论:我们的结果显示高突破感染,以及轻微的疾病课程后3理查德·道金斯SARS-CoV-2信使核糖核酸疫苗在ocrelizumab对待女士的参与者。这表明,疫苗接种的b细胞耗竭患者提供低保护突破感染。研究结果指出,需要更好的预防选项或更具体的疫苗,以便更好的临床保护。
披露:诺瓦克博士已经收到个人薪酬在500 - 4999美元的范围为在科学咨询服务或数据安全监测委员会为赛诺菲/ S。Bajwa先生没有披露。Coia教授已经收到个人薪酬制度在500 - 4999美元的范围为在科学咨询服务或数据安全监测委员会Tillotts。Coia教授已经收到个人薪酬制度在500 - 4999美元的范围在Tillotts演讲人。Coia教授的机构已经接到Tillotts研究支持。尼尔森博士已经收到相关出版物的出版版税卫生保健。尼尔森博士没有披露。河中沙洲太太没有披露。Ostergaard博士没有披露。Hvidt小姐没有披露。 Mr. BYG has nothing to disclose. Prof. Johansen has nothing to disclose. Ms. Mittl has nothing to disclose. William Rowles has nothing to disclose. Dr. Zamvil has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion. Dr. Zamvil has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Genzyme. Dr. Zamvil has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for AAN. Dr. Zamvil has received personal compensation in the range of $500-$4,999 for serving as a Advisory Board with Genzyme. Dr. Zamvil has received personal compensation in the range of $500-$4,999 for serving as a Advisory Board with Genentech. Dr. Zamvil has received personal compensation in the range of $500-$4,999 for serving as a Advisory Board with Alexion. Dr. Bove has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Bove has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon. Dr. Bove has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Bove has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Dr. Bove has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genzyme Sanofi. Dr. Bove has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Bove has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. Dr. Bove has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Jansen. Dr. Bove has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. The institution of Dr. Bove has received research support from Biogen. The institution of Dr. Bove has received research support from Roche Genentech. The institution of Dr. Bove has received research support from Novartis. Dr. Sabatino has received research support from Novartis. Dr. Sabatino has received research support from Roche/Genentech. Dr. Sabatino has received personal compensation in the range of $500-$4,999 for serving as a CME course instructor with eMultiple Sclerosis Review. Dr. Sabatino has received personal compensation in the range of $500-$4,999 for serving as a CME course instructor with Physician Education Resource. Tobias Sejbaek has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen, Merck, Novartis, Roche. Tobias Sejbaek has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen, Merck, Novartis, Teva. The institution of Tobias Sejbaek has received research support from Biogen, Merck, Novartis, Roche.
